Despite facing substantial headwinds, Pfizer's strategic pivot away from pandemic-related products is showing early signs of success. The company's second-quarter 2025 results revealed a 10% year-over ...

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

Two new real-world studies estimate the effectiveness of a single dose of a respiratory syncytial virus (RSV) vaccine against ...

Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.

This year’s Fierce Pharma Marketing Awards ceremony, which took place in Philadelphia on Wednesday night, saw several major ...

CINEHEALTH International Health and Wellness Film and Video Festival took place in conjunction with the Fierce Pharma Marketing Awards ...